Author: Smead Capital Management

On a recent business trip to Europe, we noticed—anecdotally—a lack of hope in the economic future of Europe. There is a good reason for the lack of hope. Hope, we believe, comes in the form of new life. When all of the austerity being practiced in developed nations around the world is pretty much done, something else needs to happen for economic growth to take hold. At Smead Capital Management, we believe developed economies need rebirth and the birth last week of a son to the Royal family is a watershed event. In our view, this kind of hope could be a critical factor in the success of the US large cap equity market in 2014 and beyond.

A long time friend once said, “Bill, on the stocks that worked it didn’t make any difference what you paid!” What he was referring to were the stocks which rose to many times your original purchase price and the investors who participated over the long run in the shares and ended up happy and wealthier. Is Wells Fargo (WFC) one of those companies and will Warren Buffett’s recent purchases get vindicated? As we enter the second half of 2013, this is a great discussion point for long-duration common stock investors in a market which has been strong since September of 2011. What matters most, stock market fluctuations or long-term ownership discipline?

As long-duration value investors, we at Smead Capital Management have been very attracted to the conservative accounting, shareholder friendly dividends/buybacks and bright pipeline futures of major pharmaceutical/biotech companies like Merck (MRK), Pfizer (PFE) and Amgen (AMGN). Lately, there has been weakness in these shares and we’d like to review our best theory for recent fears and price weakness, while reviewing the merit of these high quality shares.